Get 50% OFF This Summer!

Advertisement
logo

Remus Pharmaceuticals

REMUS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Remus Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a private limited company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted from a private company to public company and consequently, the name of Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad.
Company Incorporation2015
ChairmanNA
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
1,119.1
PE Ratio
55.02
Industry P/E
32.05
PEG Ratio
0
ROE
29.76%
ROCE
38.71%
ROA
17.67%
Total Debt (Cr)
20.84
Debt to Equity
0.21
Dividend Yield
0.05%
EPS
34.52
Book Value & P/B
147.41 x 12.88
Face Value
10
Outstanding Shares(Cr)
0.59
Current Ratio
2.22
EV to Sales
2.42

Stock Returns

1 Week-1.58%
1 Month-6.94%
6 Months-18.83%
1 Year+2.66%
3 Years+322.83%
5 Years+322.83%

CAGR

1 Year CAGR

Revenue Growth

N/A

Net Profit Growth

N/A

Operating Profit Growth

N/A

Dividend Growth

N/A

Stock Returns CAGR

+4.22%
no_data

No Stocks

Smart Score

2.1
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 70.85%

FIIs : 4.77%

DIIs : 0.00%

Public : 24.37%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
Promoter Shareholding Increased by 0.01% to 70.85% in March 2025 Qtr
FII Shareholding Increased by 1.61% to 4.77% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Remus Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Remus Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a private limited company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted from a private company to public company and consequently, the name of Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad.

The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries; Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers.The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency.

The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies.The product portfolio consists of 429 products, as on January 31, 2023. The Company has business to business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.

The Company is proposing an initial public issue consisting of upto 388000 Equity Shares through Fresh Issue.

Remus Pharmaceuticals Share Price

Remus Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Remus Pharmaceuticals Market Cap

Market capitalization of Remus Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Remus Pharmaceuticals is valued compared to its competitors.

Remus Pharmaceuticals PE Ratio

Remus Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Remus Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Remus Pharmaceuticals PEG Ratio

The PEG ratio of Remus Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Remus Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Remus Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Remus Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Remus Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Remus Pharmaceuticals Total Debt

Total debt of Remus Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Remus Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Remus Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Remus Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Remus Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Remus Pharmaceuticals Technical Analysis

Technical analysis of Remus Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Remus Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Remus Pharmaceuticals shares often struggle to rise above due to selling pressure.

Remus Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Remus Pharmaceuticals ’s financial health and profitability.

Remus Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Remus Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Remus Pharmaceuticals Financials

The financials of Remus Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Remus Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Remus Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Remus Pharmaceuticals .

Remus Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Remus Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Remus Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App